ES2141950T3 - Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil. - Google Patents

Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil.

Info

Publication number
ES2141950T3
ES2141950T3 ES95925087T ES95925087T ES2141950T3 ES 2141950 T3 ES2141950 T3 ES 2141950T3 ES 95925087 T ES95925087 T ES 95925087T ES 95925087 T ES95925087 T ES 95925087T ES 2141950 T3 ES2141950 T3 ES 2141950T3
Authority
ES
Spain
Prior art keywords
pct
troxerutine
topical treatment
phosfatidylcholine
complexed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95925087T
Other languages
English (en)
Inventor
Sergio Curri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inpharma SA
Original Assignee
Inpharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH02454/94A external-priority patent/CH688884A5/it
Priority claimed from CH03809/94A external-priority patent/CH688883A5/it
Application filed by Inpharma SA filed Critical Inpharma SA
Application granted granted Critical
Publication of ES2141950T3 publication Critical patent/ES2141950T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACOLOGICAS O COSMETICAS QUE MEJORAN LA MICROCIRCULACION LOCAL DEL PENE PARA EL TRATAMIENTO TOPICO, CRONICO DE LA IMPOTENCIA VASCULAR DEBIDA A CAUSAS VASCULARES, CON UNA DISFUNCION PRINCIPAL DE LOS AFERENTES ARTERIALES-ARTERIOLARES DE LOS CUERPOS CAVERNOSOS. LAS NUEVAS PROPIEDADES FARMACOLOGICAS DEL COMPLEJO ENTRE PGE1 Y/O TROXERUTINA CON FOSFATIDILCOLINA SE ADMINISTRAN LOCALMENTE SOBRE LA PIEL DEL PENE; LA ACTIVIDAD SE OBTIENE USANDO EL SISTEMA T.E.B. DE ACUERDO CON CURRI.
ES95925087T 1994-08-05 1995-07-25 Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil. Expired - Lifetime ES2141950T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH02454/94A CH688884A5 (it) 1994-08-05 1994-08-05 Composizione farmaceutica a base di troxerutina per il trattamento topico dell' impotenza erettiva peniena di origine microvascolare.
CH03809/94A CH688883A5 (it) 1994-12-16 1994-12-16 Composizione farmaceutica a base di prostaglandina E1 per il trattamento topico dell' impotenza erettiva peniena su base vascolare.

Publications (1)

Publication Number Publication Date
ES2141950T3 true ES2141950T3 (es) 2000-04-01

Family

ID=25690490

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95925087T Expired - Lifetime ES2141950T3 (es) 1994-08-05 1995-07-25 Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil.

Country Status (12)

Country Link
US (1) US6013277A (es)
EP (1) EP0722323B1 (es)
JP (1) JP3901213B2 (es)
KR (1) KR100422191B1 (es)
CN (1) CN1101192C (es)
AT (1) ATE184794T1 (es)
BR (1) BR9506301A (es)
DE (1) DE69512374T2 (es)
DK (1) DK0722323T3 (es)
ES (1) ES2141950T3 (es)
GR (1) GR3032251T3 (es)
WO (1) WO1996003991A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718917A (en) * 1995-12-15 1998-02-17 Harvard Scientific Corporation PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
WO2000051978A1 (en) * 1999-03-01 2000-09-08 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
KR100402334B1 (ko) 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
AU2003251486A1 (en) * 2002-06-12 2003-12-31 Joseph Arezzo A non-invasive, quantitative somatosensory method for the evaluation of erectile dysfunction
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
CA2830298C (en) 2011-03-17 2016-08-16 Transdermal Biotechnology, Inc. Topical nitric oxide systems comprising lecithin and methods of use thereof
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
WO2022155341A1 (en) * 2021-01-13 2022-07-21 Dyve Biosciences, Inc. Transdermal formulations for phosphodiesterase-5 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260524A (ja) * 1984-06-07 1985-12-23 Nakanishi Michio プロスタグランジン系化合物の非脂肪乳剤製剤
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
IT1247678B (it) * 1990-05-31 1994-12-28 Alberto Reale Metodo per la cura dell'impotenza erettiva maschile
DE4125255A1 (de) * 1991-07-31 1993-02-04 Knoll Ag Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung
WO1995003787A1 (en) * 1993-07-28 1995-02-09 University Of Saskatchewan Biphasic multilamellar lipid vesicles
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment

Also Published As

Publication number Publication date
CN1131912A (zh) 1996-09-25
EP0722323A1 (en) 1996-07-24
US6013277A (en) 2000-01-11
BR9506301A (pt) 1997-08-05
DE69512374T2 (de) 2000-05-11
ATE184794T1 (de) 1999-10-15
KR100422191B1 (ko) 2004-05-20
EP0722323B1 (en) 1999-09-22
MX9601298A (es) 1998-12-31
GR3032251T3 (en) 2000-04-27
JPH09503529A (ja) 1997-04-08
DK0722323T3 (da) 2000-04-03
DE69512374D1 (de) 1999-10-28
WO1996003991A1 (en) 1996-02-15
KR970701049A (ko) 1997-03-17
CN1101192C (zh) 2003-02-12
JP3901213B2 (ja) 2007-04-04

Similar Documents

Publication Publication Date Title
ES2141950T3 (es) Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil.
EE9700008A (et) Uus ravimpreparaat valu vaigistamiseks
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
NO990916L (no) Bruk av GLP-1 eller analoger i behandlingen av myokardialt infarkt
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
AR009407A1 (es) Uso de progesterona para preparar una composicion farmaceutica util para tratar o reducir la isquemia y/o una enfermedad arterial coronaria y/o laincidencia de acontecimientos cardiovasculares
DK0880350T3 (da) Behandling af dissemineret sklerose
DE69021214T2 (de) Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
MX9603596A (es) Perfluoropolieteres o composiciones de los mismos para prevencion y tratamiento de infecciones virales topicas.
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
EP1294375A4 (en) METHOD FOR THE TREATMENT OF SEBORRHOIC DERMATITIS
ES2174337T3 (es) Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
HUP9902094A2 (hu) PGE-1-tartalmú liofilizált liposzómák erekciós zavar kezelésében való alkalmazásra
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
KR900005974A (ko) 남성의 성기능 장애 치료제
ES2189886T3 (es) Composicion farmaceutica para aplicacion topica.
ES2128353T3 (es) Composicion topica que contiene penciclovir.
KR900017599A (ko) 종양 치료용 약학 조성물
SE9700617D0 (sv) New composition
MD742C2 (ro) Remediu cu activitate regenerativă
TW238246B (en) Pharmaceutical composition for reducing the renal toxicity and enhancing the effect of antitumor
ECSP961978A (es) 1- fenil- 2- dimetil-amino - metil ciclohexan ol, a procedimientos para su preparacion y la aplicación de estos compuestos en medicamentos
KR880701106A (ko) 피임제로서의 멀러리안 억제물질의 용도

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 722323

Country of ref document: ES